<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674307</url>
  </required_header>
  <id_info>
    <org_study_id>H16-01335_CARSK</org_study_id>
    <nct_id>NCT03674307</nct_id>
  </id_info>
  <brief_title>Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates</brief_title>
  <acronym>CARSK</acronym>
  <official_title>Canadian-Australasian Randomised Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for
      Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of
      non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular
      (i.e., annual) screening for CAD during wait-listing for the prevention of Major Adverse
      Cardiac Events. Secondary analyses will assess the impact of screening on the rate of
      transplantation, and the relative cost-effectiveness of screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease is the commonest cause of death while on the kidney transplant waiting
      list and after transplantation. Current standard care involves screening for coronary artery
      disease prior to waitlist entry, then every 1-2 years, according to perceived risk, until
      transplanted. The aim of screening is two-fold. Firstly to identify patients with
      asymptomatic coronary disease to enable either correction, by bypass surgery or angioplasty,
      or removal of the patient from the list, with the ultimate aim of preventing premature
      cardiovascular mortality at the time of, or soon after kidney transplantation. Secondly, from
      a societal perspective, to prevent mis-direction of scarce donor organs into recipients who
      experience early mortality. This current screening strategy is not evidence based, has
      substantial known and potential harms, and is very costly. Two major issues of uncertainty
      require addressing in sequence: (1) whether to periodically screen asymptomatic wait-listed
      patients for occult coronary artery disease; and (2) whether to revascularise coronary
      stenoses in asymptomatic patients prior to transplantation. The CARSK study seeks to address
      the first of these 2 issues.

      CARSK aims to

        1. Test the hypothesis that after screening for wait list entry, no further screening for
           coronary artery disease (CAD) is non-inferior to the current standard care which is
           screening all asymptomatic wait-listed patients for CAD at regular intervals.

        2. Compare the benefits and costs of not screening versus regular CAD screening from a
           health system perspective.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE</measure>
    <time_frame>The investigators will analyse time to first MACE event for the duration of the trial (60 months), depending on patient's date of transplant. Follow-up will be 12 months posttransplant. Maximum follow-up is 72 months.</time_frame>
    <description>Primary efficacy: major adverse cardiac event (MACE), defined as any of the following: cardiovascular death, myocardial infarction, emergency revascularisation, hospitalisation with unstable angina.
The outcome will be assessed by:
Notification to the transplant coordinators when patients are admitted in hospital (this is the usual standard of care in waitlisted patients).
The trial coordinator will gather electronic medical records, letters, procedure notes, and will fill in the relevant case record form on the REDCap database (managed by Sydney local health district). All data are encrypted and stored on servers at SLHD, where it is backed up.
Patients will be followed up 6-monthly (alternating by phone and clinic visits) where trial coordinators will discuss any hospitalisation with the patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>Between 24 and 72 months, depending on patient's date of transplant. Follow-up will be 12 months posttransplant</time_frame>
    <description>Death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency revascularisation</measure>
    <time_frame>Between 24 and 72 months, depending on patient's date of transplant. Follow-up will be 12 months posttransplant</time_frame>
    <description>Urgent, symptom-driven revascularisation for coronary artery disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Between 24 and 72 months, depending on patient's date of transplant. Follow-up will be 12 months posttransplant</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life</measure>
    <time_frame>Between 24 and 72 months, depending on patient's date of transplant. Follow-up will be 12 months posttransplant</time_frame>
    <description>health related quality of life as measured by EQ5D and/or KDQOL 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of wait-listing</measure>
    <time_frame>Between 24 and 72 months, depending on patient's date of transplant. Follow-up will be 12 months posttransplant</time_frame>
    <description>Time off the wait-list</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness</measure>
    <time_frame>The analysis will take place at the end of the study. This outcome will be followed up for 5 years.</time_frame>
    <description>Economic evaluation of the cost effectiveness of the trial from a health system perspective.
Data on resource use will be obtained in two ways. First through identification of tests, procedures and doctor's visits related to cardiac and renal management for all study participants from randomisation to study end as recorded in the patient diaries and trial case report forms. Second, Australian participants will have their records linked to the Admitted Patient Data Collection, Emergency Department Data Collection, and through Medicare for all Medicare Benefits Schedule (MBS) outpatient visits, procedures and the Pharmaceutical Benefits Scheme (PBS) for medicines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of transplantation</measure>
    <time_frame>Between 24 and 72 months, depending on patient's date of transplant. Follow-up will be 12 months posttransplant</time_frame>
    <description>incidence of transplantation between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of permanent removal from wait list for cardiac causes</measure>
    <time_frame>Between 24 and 72 months, depending on patient's date of transplant. Follow-up will be 12 months posttransplant</time_frame>
    <description>incidence of permanent removal from the wait list due to cardiac causes between the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancellation of transplantation due to coronary artery disease</measure>
    <time_frame>Between 24 and 72 months, depending on patient's date of transplant. Follow-up will be 12 months posttransplant</time_frame>
    <description>incidence of cancellation of transplantation due to coronary artery disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>Between 24 and 72 months, depending on patient's date of transplant. Follow-up will be 12 months posttransplant</time_frame>
    <description>incidence of cardiovascular death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3306</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Dialysis Related Complication</condition>
  <arm_group>
    <arm_group_label>No screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No further screening for asymptomatic coronary artery disease after wait-list entry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular screening</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No screening</intervention_name>
    <description>No further screening for asymptomatic coronary artery disease after wait-list entry</description>
    <arm_group_label>No screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Regular Screening</intervention_name>
    <description>Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry</description>
    <arm_group_label>Regular screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. adults aged 18 years of age or older

          2. Dialysis-dependent kidney failure and currently being assessed for OR active on the
             kidney transplant waiting list

          3. expected to require further screening for CAD prior to transplantation (by current
             standard of care);

          4. able to give consent;

          5. anticipated to undergo transplantation more than 12 months from date of enrolment

        Exclusion Criteria:

          1. patients with signs or symptoms suggestive of uncontrolled cardiac disease such as
             unstable coronary syndromes, decompensated heart failure, uncontrolled arrhythmia, and
             severe valvular heart disease;

          2. patients who &quot;on-hold&quot; for transplantation due to a medical problem;

          3. patients with other solid organ transplants;

          4. multi-organ transplant candidates (e.g. kidney-pancreas transplant candidates);

          5. patients with planned living donor transplant;

          6. patients unable to give consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jagbir Gill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gillian Hughes</last_name>
    <phone>1-780-782-4455</phone>
    <email>ghughes1@providencehealth.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Breanna Riou-Green</last_name>
    <phone>1-604-682-2344</phone>
    <phone_ext>64708</phone_ext>
    <email>Briougreen@providencehealth.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Kincaid</last_name>
      <email>dkincaid@mfa.gwu.edu</email>
    </contact>
    <investigator>
      <last_name>Dominic Raj</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanna Riou-Green</last_name>
      <phone>1-604-682-2344</phone>
      <phone_ext>64708</phone_ext>
      <email>Briougreen@providencehealth.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Cameron Houchmand</last_name>
      <email>chouchmand@providencehealth.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jagbir S Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John S Gill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalhousie University</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sills</last_name>
      <phone>1-902-473-7625</phone>
      <email>laura.sills@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Amanda Vinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Mazetti</last_name>
      <phone>1-905-522-1155</phone>
      <phone_ext>35368</phone_ext>
      <email>amazzett@stjosham.on.ca</email>
    </contact>
    <investigator>
      <last_name>Christine Ribic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Science Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Parsons</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>34755</phone_ext>
      <email>Samantha.parsons@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Lakshman Gunaratnam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Jevnikar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Thomas</last_name>
      <phone>1-613-738-8400</phone>
      <phone_ext>81622</phone_ext>
      <email>erithomas@toh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Julie Leidecker</last_name>
      <email>jleidecker@ohri.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Greg Knoll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Minkovich</last_name>
      <phone>1-416-340-4800</phone>
      <phone_ext>2012</phone_ext>
      <email>Michelle.Minkovich@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>S. Joseph Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Nash</last_name>
      <phone>416-867-3692</phone>
      <email>michelle.nash@unityhealth.to</email>
    </contact>
    <investigator>
      <last_name>Ramesh Prasad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval's L'Hotel-Dieu de Quebec</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>France Samson</last_name>
    </contact>
    <investigator>
      <last_name>Sacha DeSerres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Boutin</last_name>
      <phone>1-514-252-3400</phone>
      <phone_ext>6500</phone_ext>
      <email>lboutin.hmr@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Duy Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Al Ali</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>36223</phone_ext>
      <email>Cristina.Al-Ali@MUHC.MCGILL.CA</email>
    </contact>
    <contact_backup>
      <last_name>Ayat Salman</last_name>
      <email>Ayat.Salman@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo Cantarovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universite de Montreal, Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Majda Belkaid</last_name>
      <phone>514 890-8000</phone>
      <phone_ext>28241</phone_ext>
      <email>majda.belkaid.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Heloise Cardinal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeola Adesokan</last_name>
      <phone>306-978-8306</phone>
      <email>adeola.adesokan@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Rahul Mainra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martina Bertolo</last_name>
      <email>martina.bertolo@charite.de</email>
    </contact>
    <investigator>
      <last_name>Klemens Budde</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's University Hospital NHS Trust Foundation</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debasish Bannerjee, MD</last_name>
      <email>Debasish.Banerjee@stgeorges.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Debasish Bannerjee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>John Gill</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03674307/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

